Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

doi:10.1136/jnnp.2005.076869

Case Reports

. 2006 Jun;77(6):800-2.

doi: 10.1136/jnnp.2005.076869.

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

C Hirst, S Raasch, G Llewelyn, N Robertson

PMID: 16705208
PMCID: PMC2077476
DOI: 10.1136/jnnp.2005.076869

Case Reports

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

C Hirst et al. J Neurol Neurosurg Psychiatry. 2006 Jun.

. 2006 Jun;77(6):800-2.

doi: 10.1136/jnnp.2005.076869.

Authors

C Hirst, S Raasch, G Llewelyn, N Robertson

PMID: 16705208
PMCID: PMC2077476
DOI: 10.1136/jnnp.2005.076869

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

See this image and copyright information in PMC

Cited by

Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K, van Doorn PA. Kuitwaard K, et al. Drugs. 2009 May 29;69(8):987-1001. doi: 10.2165/00003495-200969080-00004. Drugs. 2009. PMID: 19496628 Review.
Pathogenesis and treatment of immune-mediated neuropathies.
Lehmann HC, Meyer Zu Horste G, Kieseier BC, Hartung HP. Lehmann HC, et al. Ther Adv Neurol Disord. 2009 Jul;2(4):261-81. doi: 10.1177/1756285609104792. Ther Adv Neurol Disord. 2009. PMID: 21179533 Free PMC article.
Novel pathomechanisms in inflammatory neuropathies.
Schafflick D, Kieseier BC, Wiendl H, Meyer Zu Horste G. Schafflick D, et al. J Neuroinflammation. 2017 Nov 28;14(1):232. doi: 10.1186/s12974-017-1001-8. J Neuroinflammation. 2017. PMID: 29179723 Free PMC article. Review.
Molecularly targeted therapies for dysimmune neuropathies.
Argyriou AA. Argyriou AA. Mol Med. 2009 Jul-Aug;15(7-8):283-7. doi: 10.2119/molmed.2009.00041. Epub 2009 May 5. Mol Med. 2009. PMID: 19593413 Free PMC article. Review.
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA. Mahdi-Rogers M, et al. Cochrane Database Syst Rev. 2017 May 8;5(5):CD003280. doi: 10.1002/14651858.CD003280.pub5. Cochrane Database Syst Rev. 2017. PMID: 28481421 Free PMC article.

See all "Cited by" articles

References

1. Van den Berg L H, Mollee I, Wokke J H.et al Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain‐Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 19955837–42. - PubMed
1. Hughes R A, Swan A V, van Doorn P A. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003(1)CD003280 - PubMed
1. Briani C, Zara G, Zambello R.et al Rituximab‐responsive CIDP. Eur J Neurol 200411788 - PubMed
1. Riechmann L, Clark M, Waldmann H.et al Reshaping human antibodies for therapy. Nature 1988332323–327. - PubMed
1. Avivi I, Chakrabarti S, Kottaridis P.et al Neurological complications following alemtuzumab‐based reduced‐intensity allogeneic transplantation. Bone Marrow Transplant 200434137–142. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Van den Berg L H, Mollee I, Wokke J H.et al Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain‐Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 19955837–42. - PubMed

[2] Van den Berg L H, Mollee I, Wokke J H.et al Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain‐Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 19955837–42. - PubMed

[3] Hughes R A, Swan A V, van Doorn P A. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003(1)CD003280 - PubMed

[4] Hughes R A, Swan A V, van Doorn P A. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003(1)CD003280 - PubMed

[5] Briani C, Zara G, Zambello R.et al Rituximab‐responsive CIDP. Eur J Neurol 200411788 - PubMed

[6] Briani C, Zara G, Zambello R.et al Rituximab‐responsive CIDP. Eur J Neurol 200411788 - PubMed

[7] Riechmann L, Clark M, Waldmann H.et al Reshaping human antibodies for therapy. Nature 1988332323–327. - PubMed

[8] Riechmann L, Clark M, Waldmann H.et al Reshaping human antibodies for therapy. Nature 1988332323–327. - PubMed

[9] Avivi I, Chakrabarti S, Kottaridis P.et al Neurological complications following alemtuzumab‐based reduced‐intensity allogeneic transplantation. Bone Marrow Transplant 200434137–142. - PubMed

[10] Avivi I, Chakrabarti S, Kottaridis P.et al Neurological complications following alemtuzumab‐based reduced‐intensity allogeneic transplantation. Bone Marrow Transplant 200434137–142. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

Authors

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources